Japanese encephalitis (JE) is a mosquito-borne virus that affects the central nervous system and is a major cause of mortality and morbidity in many parts of the world. It is estimated that there are around 68,000 cases of JE each year, resulting in around 10,000 deaths. Although the disease has been known to exist for centuries, the exact cause of the disease and its transmission remain largely unknown. This article will explore the current state of knowledge about JE, the challenges faced in controlling it, and the potential strategies for addressing this global health challenge.
Japanese encephalitis is a viral infection of the central nervous system caused by the Japanese encephalitis virus (JEV). It is a member of the Flaviviridae family, which also includes the West Nile virus, yellow fever virus, and dengue virus. JEV is transmitted to humans through the bite of an infected mosquito, usually of the genus Culex. The virus is endemic in many parts of Asia, including India, China, Japan, Korea, and Southeast Asia. The symptoms of JE can range from mild to severe, depending on the individual's age and immune status. In mild cases, symptoms may include fever, headache, nausea, and vomiting. In more severe cases, the virus can cause inflammation of the brain, leading to seizures, paralysis, and even death.
The epidemiology of JE is complex and not fully understood. It is estimated that there are around 68,000 cases of JE worldwide each year, resulting in around 10,000 deaths. The highest incidence of JE is seen in rural areas of Asia, particularly in India, China, Japan, and Southeast Asia. The transmission of JE is closely linked to the ecology of the mosquito vector. The virus is most commonly transmitted during the rainy season when the number of mosquitoes is highest. The virus is also spread through the migration of infected birds, which can serve as a reservoir for the virus.
The diagnosis of JE is based on clinical symptoms as well as laboratory testing. The most commonly used laboratory test is the enzyme-linked immunosorbent assay (ELISA), which detects the presence of antibodies to the JEV. Other tests, such as polymerase chain reaction (PCR), can also be used to detect the virus itself. There is no specific treatment for JE, and management is largely supportive. The mainstay of treatment is supportive care, including the use of antipyretics, analgesics, and anticonvulsants. In severe cases, intensive care may be necessary.
The best way to prevent JE is to reduce the risk of mosquito bites. This can be done by using insect repellents, wearing long-sleeved clothing, and avoiding areas where mosquitoes are known to be present. Vaccination is the most effective way to protect against JE. Currently, there are two types of JE vaccines available: an inactivated vaccine and a live attenuated vaccine. The inactivated vaccine is recommended for adults and children over the age of two months, while the live attenuated vaccine is recommended for children under the age of two months. In addition to vaccination, vector control measures, such as the use of insecticides and larvicides, can also be used to reduce the risk of transmission.
Japanese encephalitis is a mosquito-borne virus that affects the central nervous system and is a major cause of mortality and morbidity in many parts of the world. Despite its long history, the exact cause of the disease and its transmission remain largely unknown. The best way to prevent JE is through vaccination and vector control measures, such as the use of insecticides and larvicides. There is no specific treatment for JE, and management is largely supportive.
1.
Obesity linked to subsequent neoplasms in childhood cancer survivors
2.
We don't all need regular skin cancer screening?but you can know your risk and check yourself
3.
Global inequalities found in cancer research funding
4.
A US health panel advises starting mammograms at age 40 rather than 50.
5.
Clinical trial results show low-intensity therapy can achieve positive outcomes for certain pediatric leukemia subtypes
1.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
2.
Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications
3.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
4.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
5.
The Converging Frontiers of Radiation Oncology and Systemic Therapies by 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
4.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation